CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Creative Commons License

Misra A. C. , Luker K. E. , Durmaz H., Luker G. D. , LAHANN J.

BIOMACROMOLECULES, vol.16, no.8, pp.2412-2417, 2015 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 8
  • Publication Date: 2015
  • Doi Number: 10.1021/acs.biomac.5b00653
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.2412-2417


CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1'[1,4-phenylenebis(methylene)This[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies.